Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
Gillessen S, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Bulbul M, Caffo O, Chi K, Clarke C, Clarke N, Davis I, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke O, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman M, Hussain M, James N, Jones R, Kanesvaran R, Khauli R, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg C, Suzuki H, Sweeney C, Sydes M, Taplin M, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology 2022, 82: 115-141. PMID: 35450732, DOI: 10.1016/j.eururo.2022.04.002.Peer-Reviewed Original ResearchConceptsAdvanced Prostate Cancer Consensus ConferenceProstate Cancer Consensus ConferenceAdvanced prostate cancerMetastatic hormone-sensitive prostate cancerProstate cancerConsensus conferenceTreatment optionsDiagnosed metastatic hormone-sensitive prostate cancerManagement of advanced prostate cancerTreatment of advanced prostate cancerProstate-specific membrane antigen ligandHormone-sensitive prostate cancerInternational prostate cancer expertsConsensus questionsProstate cancer expertsLevel 1 evidenceManagement of patientsLocation of diseaseExpert panel votesClinically relevant areasSupplementation guidelinesClinical evidencePatient characteristicsAntigenic ligandsClinical trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply